BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 9316641)

  • 1. Immunosensitization of prostate carcinoma cell lines for lymphocytes (CTL, TIL, LAK)-mediated apoptosis via the Fas-Fas-ligand pathway of cytotoxicity.
    Frost P; Ng CP; Belldegrun A; Bonavida B
    Cell Immunol; 1997 Aug; 180(1):70-83. PubMed ID: 9316641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemosensitization of human prostate carcinoma cell lines to anti-fas-mediated cytotoxicity and apoptosis.
    Uslu R; Borsellino N; Frost P; Gárban H; Ng CP; Mizutani Y; Belldegrun A; Bonavida B
    Clin Cancer Res; 1997 Jun; 3(6):963-72. PubMed ID: 9815772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunosensitization of resistant human tumor cells to cytotoxicity by tumor infiltrating lymphocytes.
    Frost P; Caliliw R; Belldegrun A; Bonavida B
    Int J Oncol; 2003 Feb; 22(2):431-7. PubMed ID: 12527945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitization of immunoresistant prostate carcinoma cell lines to Fas/Fas ligand-mediated killing by cytotoxic lymphocytes: independence of de novo protein synthesis.
    Frost PJ; Belldegrun A; Bonavida B
    Prostate; 1999 Sep; 41(1):20-30. PubMed ID: 10440872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitization of human ovarian tumor cells by subtoxic CDDP to anti-fas antibody-mediated cytotoxicity and apoptosis.
    Uslu R; Jewett A; Bonavida B
    Gynecol Oncol; 1996 Aug; 62(2):282-91. PubMed ID: 8751562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II).
    Mizutani Y; Yoshida O; Bonavida B
    J Urol; 1998 Aug; 160(2):561-70. PubMed ID: 9679929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunosensitization of melanoma tumor cells to non-MHC Fas-mediated killing by MART-1-specific CTL cultures.
    Frost PJ; Butterfield LH; Dissette VB; Economou JS; Bonavida B
    J Immunol; 2001 Mar; 166(5):3564-73. PubMed ID: 11207317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dimethyl 2,2-dichlorovinyl phosphate (DDVP) markedly inhibits activities of natural killer cells, cytotoxic T lymphocytes and lymphokine-activated killer cells via the Fas-ligand/Fas pathway in perforin-knockout (PKO) mice.
    Li Q; Nakadai A; Takeda K; Kawada T
    Toxicology; 2004 Nov; 204(1):41-50. PubMed ID: 15369847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perforin-mediated lysis of tumor cells by Mycobacterium bovis Bacillus Calmette-Guérin-activated killer cells.
    Brandau S; Suttmann H; Riemensberger J; Seitzer U; Arnold J; Durek C; Jocham D; Flad HD; Böhle A
    Clin Cancer Res; 2000 Sep; 6(9):3729-38. PubMed ID: 10999767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perforin, Fas ligand, and tumor necrosis factor are the major cytotoxic molecules used by lymphokine-activated killer cells.
    Lee RK; Spielman J; Zhao DY; Olsen KJ; Podack ER
    J Immunol; 1996 Sep; 157(5):1919-25. PubMed ID: 8757310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiestrogens affect both pathways of killer cell-mediated oncolysis.
    Haeryfar SM; Nagy E; Baral E; Krepart G; Lotocki R; Berczi I
    Anticancer Res; 2000; 20(3A):1849-53. PubMed ID: 10928117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing.
    Rivoltini L; Radrizzani M; Accornero P; Squarcina P; Chiodoni C; Mazzocchi A; Castelli C; Tarsini P; Viggiano V; Belli F; Colombo MP; Parmiani G
    J Immunol; 1998 Aug; 161(3):1220-30. PubMed ID: 9686582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of Fas ligand and Fas-mediated pathway in the cytotoxicity of human natural killer cells.
    Oshimi Y; Oda S; Honda Y; Nagata S; Miyazaki S
    J Immunol; 1996 Oct; 157(7):2909-15. PubMed ID: 8816396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perforin, Fas/Fas ligand, and TNF-alpha pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL.
    Ando K; Hiroishi K; Kaneko T; Moriyama T; Muto Y; Kayagaki N; Yagita H; Okumura K; Imawari M
    J Immunol; 1997 Jun; 158(11):5283-91. PubMed ID: 9164947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular mechanisms of immune-mediated lysis of murine renal cancer: differential contributions of perforin-dependent versus Fas-mediated pathways in lysis by NK and T cells.
    Sayers TJ; Brooks AD; Lee JK; Fenton RG; Komschlies KL; Wigginton JM; Winkler-Pickett R; Wiltrout RH
    J Immunol; 1998 Oct; 161(8):3957-65. PubMed ID: 9780164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines.
    Borsellino N; Belldegrun A; Bonavida B
    Cancer Res; 1995 Oct; 55(20):4633-9. PubMed ID: 7553641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The mechanism of organophosphorus pesticide-induced inhibition of cytolytic activity of killer cells.
    Li Q; Kawada T
    Cell Mol Immunol; 2006 Jun; 3(3):171-8. PubMed ID: 16893497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral cancer cell lines can use multiple ligands, including Fas-L, TRAIL and TNF-alpha, to induce apoptosis in Jurkat T cells: possible mechanisms for immune escape by head and neck cancers.
    Kassouf N; Thornhill MH
    Oral Oncol; 2008 Jul; 44(7):672-82. PubMed ID: 17996489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acidic pH inhibits non-MHC-restricted killer cell functions.
    Fischer B; Müller B; Fischer KG; Baur N; Kreutz W
    Clin Immunol; 2000 Sep; 96(3):252-63. PubMed ID: 10964544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively.
    Hashimoto W; Osaki T; Okamura H; Robbins PD; Kurimoto M; Nagata S; Lotze MT; Tahara H
    J Immunol; 1999 Jul; 163(2):583-9. PubMed ID: 10395644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.